» Articles » PMID: 31500138

Cardiovascular Risk/Benefit Profile of MHT

Overview
Publisher MDPI
Specialty General Medicine
Date 2019 Sep 11
PMID 31500138
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Data emerging from the Women's Health Initiative (WHI) study point toward an association between menopausal hormone therapy (MHT) and cardiovascular (CV) risk. However, post hoc subgroup analyses stratifying participants according to their age and time since menopause, have opened the way to a better understanding of the relationship between estrogen and CV risk. The aim of this review was to revise the current literature and evaluate the CV risk or benefit following administration of MHT considering several factors such as MHT timing, dose, route of administration, and formulation. : An electronic databases search of MEDLINE (PubMed), Cochrane Central Register of Controlled Trials, Web of Science, SCOPUS, congress abstracts, and Grey literature (Google Scholar; British Library) was performed, with the date range from each database's inception until June 2019. All the studies evaluating MHT and cardiovascular risk, including thromboembolism or stroke, were selected: Timing of MHT initiation was shown to be a critical factor in CV risk assessment. In concordance with the "timing hypothesis", healthy symptomatic women who initiated MHT when aged younger than 60 years, or who were within 10 years of menopause onset, have demonstrated a reduction in both coronary heart disease (CHD) risk and all-cause mortality. In particular, MHT therapy was associated with improvement of subclinical signs of atherosclerosis. Venous thromboembolism (VTE) risk is reduced when low doses of oral estrogen are used. Moreover, transdermal hormonal application significantly reduces CV risk compared with oral administration. MHT impact on the CV system is influenced by either factors inherent to the specific regimen, or factors inherent to the specific patient. Hence, individualization of care is necessary. : CV risk calculation should be considered by clinicians in order to exclude patients with high CV risk, in whom MHT is contraindicated. Assessing risks and benefits in a patient-centered approach according to individual's features, health status, and personal preferences is important in order to realize a safe and effective treatment.

Citing Articles

The Impact of Menopause on Cardiovascular Aging: A Comprehensive Review of Androgen Influences.

Raj A, Chakole S, Agrawal S, Gupta A, Khekade H, Prasad R Cureus. 2023; 15(8):e43569.

PMID: 37719547 PMC: 10503403. DOI: 10.7759/cureus.43569.

References
1.
Stuenkel C, Davis S, Gompel A, Lumsden M, Murad M, Pinkerton J . Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11):3975-4011. DOI: 10.1210/jc.2015-2236. View

2.
Hersh A, Stefanick M, Stafford R . National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291(1):47-53. DOI: 10.1001/jama.291.1.47. View

3.
Manson J . Current recommendations: what is the clinician to do?. Fertil Steril. 2014; 101(4):916-21. DOI: 10.1016/j.fertnstert.2014.02.043. View

4.
Komm B, Thompson J, Mirkin S . Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials. Climacteric. 2014; 18(4):503-11. DOI: 10.3109/13697137.2014.992011. View

5.
Manson J, Chlebowski R, Stefanick M, Aragaki A, Rossouw J, Prentice R . Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13):1353-68. PMC: 3963523. DOI: 10.1001/jama.2013.278040. View